XML 55 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value (Narrative) (Details)
$ in Thousands
 12 Months Ended 48 Months Ended
Oct. 13, 2015
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Change in value of contingent consideration   $ (4,078) $ 969  
Scenario, Forecast [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration revenue to target ratio       1.5
Payment of contingent consideration when commercial milestone achieved time allotment period       65 days
nContact Surgical [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Change in value of contingent consideration   4,078 $ 969  
Fair value of AtriCure common stock issued at closing $ 3,757 5,660    
Patient Enrollment In Converge IDE Trial [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Change in value of contingent consideration   $ 7,500    
Number of days payment due following enrollment   30 days    
Completion Of CONVERGE IDE Trial And Receiving A PMA From FDA [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Potential contingent consideration reduction, percentage   8.33%    
Potential contingent consideration reduction if regulatory milestone not met   $ 0    
Number of days payment due following receipt of approval   30 days    
Maximum [Member] | Completion Of CONVERGE IDE Trial And Receiving A PMA From FDA [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Change in value of contingent consideration   $ 42,500